NSE: CIPLA · 27 October 2026
- Cipla Ltd. (CIPLA) fell 0.94% on October 27, 2026, closing at ₹1,342.30 against its previous close of ₹1,355.00. The stock traded within a daily range of ₹1,319.30 and ₹1,372.70.
- Cipla Q2 results: Net profit plunges 35% to Rs 878 crore, revenue down 2.4% YoY; stock falls Moneycontrol.com
- Trading volume was 3.67 times the 20-day average daily volume.
Why is CIPLA share price falling on 27 October 2026?
Cipla Ltd. (CIPLA) fell 0.94% on October 27, 2026, closing at ₹1,342.30 against its previous close of ₹1,355.00. The stock traded within a daily range of ₹1,319.30 and ₹1,372.70.
While the broader Nifty index was essentially flat with a minor drop of 0.02%, the sector benchmark Nifty Pharma outperformed significantly, advancing 2.06% during the trading day. Cipla's decline of 0.94% contrasted with the wider positive momentum observed across the pharmaceutical sector, reflecting individual stock headwinds or profit-taking despite favorable sectoral tailwinds.
35.85 lakh shares traded by 27 October 2026 · 02:55 PM IST. This compares with a 20-day average daily volume of 9.78 lakh shares (3.67 times). The five-day average daily volume was 12.27 lakh shares. Separately, the NSE report for 26 October 2026 showed 7.70 lakh shares delivered, representing 49.74% of that day’s traded volume. The same report recorded 41,675 trades.
Cipla's decline of 0.94% amid heavy volume (3.67x of 20-day average) occurred on the same day it reported its Q2FY27 financial results. While the Nifty Pharma sector gained 2.06%, the stock faced selling pressure or profit-taking as investors evaluated the reported financial metrics.
Latest Company Developments
Cipla Q2 results: Net profit plunges 35% to Rs 878 crore, revenue down 2.4% YoY; stock falls Moneycontrol.com
Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company.
a press release dated September 03, 2026, titled "Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 20.78% on 30 September 2026. This compares with 20.56% on 30 June 2026, a change of +0.22 percentage points.
The filing reported 46 MF/UTI holders.
What to Watch Next
- Management commentary and investor conference call discussion regarding Q2FY27 margins and geographical segment performance
- Execution progress on North American pipeline products including gAdvair Diskus and the Keytruda biosimilar partnership with Qilu Pharmaceutical
- Volume trends and delivery participation following the heavy trading activity observed on October 27, 2026
- Secondary market growth trajectory for One-India and South Africa private business segments
Other Dated Coverage
- CIPLA Share Price Today: Why CIPLA Is Falling 0.44% | 23 October 2026 — 23 October 2026
- Why Cipla Shares Dropped 2.41% Today: Sector Trends & Outlook | 30 September 2026 — 30 September 2026
More CIPLA news and dated analysis →
Frequently Asked Questions
What is the latest CIPLA company news?
Cipla Q2 results: Net profit plunges 35% to Rs 878 crore, revenue down 2.4% YoY; stock falls Moneycontrol.com
How strong was CIPLA’s trading volume?
35.85 lakh shares traded, 3.67 times the 20-day average daily volume. The price and volume data are dated 27 October 2026 · 02:55 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.